We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

62 hedge funds and large institutions have $66.3M invested in Lineage Cell Therapeutics in 2014 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 11 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

127% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 11

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

15% more capital invested

Capital invested by funds: $57.6M → $66.3M (+$8.69M)

7% more funds holding

Funds holding: 58 → 62 (+4)

4.98% more ownership

Funds ownership: 32.33% → 37.31% (+5%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

98% less call options, than puts

Call options by funds: $4K | Put options by funds: $199K

Holders
62
Holders Change
+4
Holders Change %
+6.9%
% of All Funds
1.78%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
10
Increased
25
Reduced
11
Closed
6
Calls
$4K
Puts
$199K
Net Calls
-$195K
Net Calls Change
-$70K

Top Buyers

1
BC
Broadwood Capital
New York
+$10.1M
2
BFA
BlackRock Fund Advisors
California
+$556K
3
WSCM
Wellington Shields Capital Management
New York
+$410K
4
BIT
BlackRock Institutional Trust
California
+$286K
5
VKH
Virtu KCG Holdings
New York
+$133K

Top Sellers

1
CS
Credit Suisse
Switzerland
-$180K
2
Renaissance Technologies
Renaissance Technologies
New York
-$170K
3
Goldman Sachs
Goldman Sachs
New York
-$160K
4
Swiss National Bank
Swiss National Bank
Switzerland
-$93K
5
Deutsche Bank
Deutsche Bank
Germany
-$71.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
NFA
26
Nationwide Fund Advisors
Ohio
$119K +$28K +12,384 +34%
Manulife (Manufacturers Life Insurance)
27
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$114K +$14.8K +6,558 +16%
AIG
28
American International Group
New York
$111K +$24.7K +10,942 +32%
Bank of America
29
Bank of America
North Carolina
$106K +$80.6K +35,706 +498%
RhumbLine Advisers
30
RhumbLine Advisers
Massachusetts
$88K +$13.1K +5,798 +19%
ProShare Advisors
31
ProShare Advisors
Maryland
$77K -$33.7K -14,907 -32%
GC
32
Guggenheim Capital
Illinois
$77K -$1.99K -880 -3%
AFG
33
Albion Financial Group
Utah
$70K – – –
State Board of Administration of Florida Retirement System
34
State Board of Administration of Florida Retirement System
Florida
$69K – – –
Jane Street
35
Jane Street
New York
$69K +$63.3K +28,036 New
SCP
36
Seizert Capital Partners
Michigan
$61K – – –
Group One Trading
37
Group One Trading
Illinois
$53K +$25.7K +11,358 +113%
Millennium Management
38
Millennium Management
New York
$53K +$48.7K +21,559 New
CS
39
Credit Suisse
Switzerland
$47K -$180K -79,757 -81%
Barclays
40
Barclays
United Kingdom
$42K +$10.9K +4,833 +39%
Goldman Sachs
41
Goldman Sachs
New York
$37K -$160K -70,683 -83%
Citadel Advisors
42
Citadel Advisors
Florida
$34K -$7.33K -3,244 -19%
WEC
43
Winslow Evans & Crocker
Massachusetts
$33.5K +$14K +6,195 +83%
Wells Fargo
44
Wells Fargo
California
$27K +$14.5K +6,425 +141%
PCM
45
Prelude Capital Management
New York
$23K +$2.1K +929 +11%
U
46
UBS
Switzerland
$14K -$29.3K -12,962 -70%
VFA
47
Virtus Fund Advisers
Connecticut
$14K +$12.4K +5,501 New
Fifth Third Bancorp
48
Fifth Third Bancorp
Ohio
$13K – – –
Royal Bank of Canada
49
Royal Bank of Canada
Ontario, Canada
$10K – – –
Bank of Montreal
50
Bank of Montreal
Ontario, Canada
$7K +$6.38K +2,825 New
1
2
3

LCTX Hedge Fund Activity: Q2 2014 in Review

62 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q2 2014, worth a combined $66.3M — up 15% from $57.6M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new LCTX positions and 6 closed out — a net gain of 4 holders — while 25 added to existing stakes and 11 trimmed.

The largest buyer was Broadwood Capital, adding an estimated $10.1M. The largest seller was Credit Suisse, cutting an estimated $180K.

  • 62 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q2 2014, up from 58 in Q1 2014.
  • Funds reported $66.3M of Lineage Cell Therapeutics stock for Q2 2014, up 15% quarter-over-quarter.
  • 10 funds opened new Lineage Cell Therapeutics positions in Q2 2014 and 6 closed out, a net change of +4 holders.
  • The largest Lineage Cell Therapeutics buyer in Q2 2014 was Broadwood Capital, an estimated $10.1M added.
  • The largest Lineage Cell Therapeutics seller in Q2 2014 was Credit Suisse, an estimated $180K sold.

Based on aggregated 13F filings for Q2 2014.